In recent years, improved knowledge of melanoma pathogenesis has led to the development of BRAF and MEK inhibitors that target tumours carrying BRAF oncogenic mutations, accounting for 40%–50% of all melanoma cases. This evidence concerns the gene BRAF and neoplasm.